VISACards AcceptedFree Shipping Over $300GTA Third-Party TestedHPLC Purity and Bacterial Endotoxin TestedShips Canada-Wide3+ Vials — 10% Off5+ Vials — 20% Off10+ Vials — 40% OffVISACards AcceptedFree Shipping Over $300GTA Third-Party TestedHPLC Purity and Bacterial Endotoxin TestedShips Canada-Wide3+ Vials — 10% Off5+ Vials — 20% Off10+ Vials — 40% Off
Out of stock

Eloralintide

10 mg (lyophilized)

Purity:

TBD

Eloralintide 10 mg (lyophilized) research vial

Cap colour is for illustration purposes only

Research peptide · RUO · Canada

Eloralintide

10 mg (lyophilized)

Formula
N/ACAD · per vial

+ $25 flat-rate shipping · free at $300+ · Interac e-Transfer · VISA

1
Inquire
PurityTBD
Storage-20°C
FormLyophilized
TestingHPLC
🏦Interac e-Transfer
COA policy·Returns

About this compound

Eloralintide (development code LY3841136) is a synthetic, long-acting analogue of amylin, a 37-amino acid peptide hormone co-secreted with insulin by pancreatic beta cells. It is characterised as a selective agonist of the amylin 1 receptor (AMY1R), with approximately 12-fold greater potency at AMY1R than at the calcitonin receptor, a selectivity profile that distinguishes it from earlier amylin analogues that activate both receptor types. It has been used in research on satiety signalling, appetite regulation and body-weight pathways, alone and alongside incretin-based compounds. Currently out of stock. Batch COA and full details will be posted once third-party testing is complete.

Storage and handling

Lyophilized storage

Store at -20°C lyophilized, away from moisture and UV light. Keep vials sealed until use. Stable for 2+ years in a non-frost-free freezer.

Preclinical research references

Provided for informational context only. All cited studies involve preclinical or in vitro models. Results do not predict human safety or efficacy. These references do not constitute medical claims.

  • Receptor pharmacology work characterised eloralintide as a selective AMY1R agonist, with approximately 12-fold greater potency at AMY1R than at the calcitonin receptor (Eli Lilly, LY3841136 development programme)
  • A Phase 2 dose-ranging trial of once-weekly eloralintide in adults over 48 weeks, examining dose-dependent body weight change versus placebo, was published in The Lancet in November 2025 (PMID 41207310)
  • Add-on studies combining eloralintide with ongoing tirzepatide reported additive effects on body weight and fat mass over 4 weeks (Eli Lilly, ADA 2026 scientific presentation)

Shipping & returns

Shipping

1–5 business days (5–7 for BC, NL and remote areas), Canada-wide tracked courier, double tamper-proof packaging.

Returns

All sales final. Damaged or incorrect orders must be reported within 24 hours with photos.

Quality assurance

Every batch independently tested for purity. COA on file and available before purchase.

FAQ — Eloralintide

For research use only. Not for human or veterinary administration.

Research updates

Stay ahead of new batches.

New compounds, COA releases, batch testing results, and research content — straight to your inbox.

Research Use Only (RUO): All products are strictly for laboratory research. Not for human or veterinary use. Full disclaimer →